City page
Umea biotech and pharma directory
This page shows why the city matters, which categories are strongest there, and which compliance or quality markers are already visible in public evidence.
Where does this city read strongest?
Therapeutics (2), Diagnostics (1), and CRO (1). Most visible records: InfiCure Bio, Lipum, and Lipigon Pharmaceuticals.
Which standards and public evidence are already visible?
ISO-13485 (1). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Umea.
By category
Umea by category
Jump into a category page filtered to this country only.
Full list
Umea biotech and pharma directory
4 city records currently match the active filter.
Current review cycle
InfiCure Bio
UmeaSwedenCRO
Umea preclinical CRO built around the proprietary NIF mouse model, supplying in vivo efficacy readouts for anti-fibrotic and anti-inflammatory drug candidates across liver and kidney programs.
- Lead
- Sofia MayansCo-Founder and Chief Executive Officer
- Scale
- Preclinical contract research
Current review cycle
Lipum
UmeaSwedenTherapeutics
Umea biopharma company developing first-in-class anti-inflammatory therapeutics for chronic inflammatory disease from its northern Sweden headquarters.
- Lead
- Ola SandborghCEO
- Scale
- Preclinical therapeutics platform
Current review cycle
Lipigon Pharmaceuticals
UmeaSwedenTherapeutics
Umea therapeutics company focused on lipid-metabolism and severe-dyslipidemia drug development from its northern Sweden research base.
- Lead
- Johan LiwingCEO
- Scale
- Preclinical therapeutics platform
Current review cycle
Nordic Biomarker
UmeaSwedenDiagnostics
Umea diagnostics and assay company supplying coagulation and hemostasis reagents, with certified quality systems and Swedish manufacturing-related operating depth.
- Lead
- Rikard RodenCEO
- Scale
- Diagnostics and reagent platform
Related briefs
Briefs that mention Umea
Nordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefEuropean Antibody & Biosimilar Therapeutics 2026: mAbs, ADCs, Biosimilars
A practical map of the European antibody + antibody-drug-conjugate + biosimilar therapeutics sector in 2026 — Genmab, ADC Therapeutics, Adcendo, Affimed, Tubulis, Heidelberg Pharma, Sandoz, Mabion, plus a Swedish + Swiss + Polish antibody innovator belt.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.